From Oxford: Carlo Rinaldi's team has received two grants from Oxford-Harrington Rare Disease Centre to develop treatments for Spinal-bulbar muscular atrophy (SBMA) and Friedreich's ataxia
He describes his work in these diseases and how Oxford-Harrington has provided funding and advice that has been valuable beyond the feedback he typically receives in an academic setting.
3 days ago
From Oxford: Professor Matthew Wood describes the Oxford-Harrington Rare Disease Centre, a transatlantic effort to accelerate drug development for rare diseases
He highlights the centre's Scholars program, which researchers anywhere can apply for and funds ten new drug development programs each year. Plus the centre's accelerator program and plans for a rare disease investment fund. He also discusses how regulatory changes at places like MHRA can help the rare disease community.
3 days ago
Biotech CEOs discuss the state of the industry, what is needed to compete globally, the importance of having a patient-centric approach, and more
MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Aurora Therapeutics CEO Ed Kaye and DaCapo Brainscience CEO Leslie Williams about being biotech leaders during this volatile time for the industry. They stress that a key to success is that everyone in the industry work together towards shared goals. Chapters Introductions - 1:19 Aurora Therapeutics - 5:34 DaCapo Brainscience - 9:37 Being patient centric - 11:00 The state of the industry - 19:04 Mas
Feb 12
Analyst Thursdays: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened
He discusses upcoming readouts for IDEAYA Biosciences, Ocular Therapeutix (how it might affect EyePoint), and Palvella Therapeutics. Plus, his take on the recent Corvus atopic dermatitis data. Chapters IDEAYA Biosciences - 0:46 EyePoint / Ocular - 3:45 Palvella - 7:43 Corvus - 12:30
Feb 12
The Massachusetts Life Sciences Center hosted Convening of the Cores at The Engine in Cambridge today to showcase publicly-available scientific equipment and facilities biotech companies can access
MLSC's President & CEO Kirk Taylor, MD describes the organization's mission, how biotech startups and others can search for and utilize equipment and facilities that might otherwise be out of reach, and his take on the current state of the ecosystem.
Feb 10
NYSE Market Strategist Eric Criscuolo discusses how the newly appointed Federal Reserve Chair and other market factors might affect the biotech sector
He discusses interest rates, generalist investor participation in the sector, and more.
Feb 2
.png){kind=logo}
